Clinical trials: Healthy Humans
Healthy
A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects
This is a FIH, randomized, double- blind, placebo-controlled, dose -escalation study to investigate the safety, tolerability, PK, and PD of ENN0403 after single and multiple oral dose administration in healthy adult subjects.
- Trial name
- NCT05506540
- Testing
- ENN0403 1mg, ENN0403 4mg, ENN0403 10mg
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- EnnovaBio
Influenza, Human
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
Background: Vaccines are substances used to try to create resistance or immunity to a disease and to prevent an infection. Investigators are looking into improved ways to give and test the results of different kinds of vaccines.
- Trial name
- NCT00995982
- Testing
- VRC-FLUDNA056-00VP
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
- Trial name
- NCT03076385
- Testing
- VAL-506440
- Where
- Germany
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Safety Issues, Tolerance
Study to Evaluate LPH-5 in Healthy Subjects
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.
- Trial name
- NCT06722820
- Testing
- LPH-5
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Lophora
Spinal Cord Injuries, Traumatic Spinal Cord Injury
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
The purpose of this observational research study is to better understand immune responses to vaccines against viruses (influenza or SARS-CoV2).
- Conditions
- Spinal Cord Injuries, Traumatic Spinal Cord Injury, Healthy Controls, Flu Vaccine
- Trial name
- SCIVAX (NCT05869968)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Healthy, Immune System and Related Disorders
The Healthy Human Global Project - Hong Kong (HHGP-Hong Kong)
The Healthy Human Global Project-Hong Kong aims to elucidate the heritable and non-heritable factors that drive immunological variance within a healthy population in Hong Kong.
- Trial name
- NCT05174624
- Testing
- No intervention
- Where
- China
- Volunteers
- 1,026 people, healthy volunteers welcome
- Sponsor
- Centre for Immunology & Infection
Healthy
Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt controlled-release test tablet formulation of oxycodone 40 mg compared to an equivalent oral…
- Trial name
- NCT00853268
- Testing
- Controlled-Release Oxycodone Hydrochloride 40 mg, OxyContin® 40 mg tablet
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Healthy Volunteers
A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06266047 after first-time administration to healthy adult subjects.
- Trial name
- NCT02539550
- Testing
- PF-06266047
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infection, Human Immunodeficiency Virus
Evaluation of the Bioequivalence of a Combined Formulated Tablet
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01622790
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cough
First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383
This is a first-in-human study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of HS-10383 using a randomized, double blind, placebo controlled, single center study design.
- Trial name
- NCT05429723
- Testing
- HS-10383
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Healthy
A Clinical Study of BG136 Injection in Healthy Chinese Volunteers
This is a first-in-human, randomized, double-blind, placebo-controlled trial in healthy subjects. The trial consisted of two parts: part 1: single ascending dose (SAD) study and part 2: multiple ascending dose (MAD) study.
- Trial name
- NCT05984368
- Testing
- BG136
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
HIV Infection, Infection, Human Immunodeficiency Virus
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
This study is a two-part study. Part one is designed to see how different formulations of GSK364735 are absorbed in the body and To see how food affects how GSK364735 is absorbed in the body.
- Trial name
- NCT00386347
- Testing
- GSK364735 oral solution and oral tablets
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine Response Impaired
Antibiotics and Vaccine Immune Responses Study
The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination.
- Trial name
- AVIRS (NCT06148025)
- Testing
- BCG vaccine, Yellow Fever vaccine, Vancomycin Oral Capsule
- Where
- Australia
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- South Australian Health and Medical Research Institute
Influenza, Human
Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
This is a Phase 1, first-in-human, randomized, placebo-controlled, observer blind study. The effect of two doses of an investigational vaccine on safety, reactogenicity, kinetics and magnitude of the post-vaccination antibody…
- Trial name
- NCT06028347
- Testing
- sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Seqirus
Healthy
Investigations Regarding B-cell Subsets in Humans
The aim of this research is to define the human equivalent of mouse B1 cells.
- Trial name
- NCT00926692
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Autoimmune Diseases
Phase 0 Microdose Study
This study is a methodology study to evaluate a microdose strategy for Drug-Drug Interaction (DDI) which will be useful in the evaluation of the backup compounds for GSK706769, as well as possibly other assets.
- Trial name
- NCT00975936
- Testing
- [14C]-GSK706769, Ketoconazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Aging, Healthy Aging
FAXAGE: Fasting And Exercise To Slow Aging In Humans
FAXAge is a randomized controlled trial investigating the effects of fasting and exercise on human aging. 240 participants over the age of 65 will be divided into 4 groups - an exercise group, a fasting group, a combined exercise…
- Conditions
- Aging, Healthy Aging, Aging Frailty
- Trial name
- FAXAGE (NCT07207044)
- Testing
- Exercise - Strength + Cardio, Time-restricted feeding, Time-restricted feeding + Exercise
- Where
- Denmark
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Chronic Hepatitis B
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
This is the first in human study of 162, and the primary objective is to evaluate the safety and tolerability of 162 with a single ascending dose in healthy adult subjects.
- Trial name
- NCT05310487
- Testing
- 162
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yangshengtang Co., Ltd
Healthy Subjects
A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males
This is a first time in human study to assess the safety and tolerability of AZD1979 following oral administration of single ascending doses in healthy male volunteers.
- Trial name
- NCT02072993
- Testing
- AZD1979
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
HIV Antibodies
Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Background: The experimental product in this study, N6LS, is a human monoclonal antibody. Antibodies are one way that the human body fights infection. Monoclonal means that all the antibodies in the product are the same.
- Trial name
- VRC 609 (NCT03538626)
- Testing
- VRC-HIVMAB091-00-AB, rHuPH20
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.